Introduction
Gram-negative bacteria are common pathogens of man. Lipopolysaccharides (LPS),1 or endotoxins, are an essential structural and immunopathogenic component ofthe outer cell membrane of all gram-negative bacteria (1, 2) . LPS are complex, microheterogeneous macromolecules that share a tripartite structure that consists of lipid A, the core oligosaccharide, and O-specific side chain (3) . Lipid A is the toxic moiety, and together with the covalently attached core oligosaccharide, constitutes the phy- (5, 6) .
It has been proposed that antibodies that recognized conserved epitopes in the core-lipid A region of LPS would crossreact among a wide variety ofgram-negative bacteria and would possess antiendotoxic activity based on their ability to neutralize or block lipid A-mediated biological activities (7) . It has been further speculated that such antibodies, because of their broad cross-reactivity and putative antiendotoxic properties, would serve a protective function in gram-negative sepsis of diverse etiology. Moreover, since serum antibodies that react with LPS core determinants are prevalent among normal adults (8, 9), these antibodies have been regarded as an important component of natural immunity against gram-negative bacterial disease. Accordingly, augmentation ofsuch antibodies through active or passive immunization has been viewed as a potential means for increasing host resistance to the septic complications of gramnegative infections. This possibility has been evaluated, both in experimental animals (10, 11) and in man (12) , through immunization with rough mutants ofcertain gram-negative bacteria whose incomplete LPS is comprised of antigenically exposed core structures containing lipid A and basal core sugars (5, 13) . These studies have proven inconclusive, however, on the basis of variable protection or the failure to correlate protection with antibodies of defined specificity.
The availability of monoclonal antibodies (mAbs) with specificities for well-defined epitopes in the LPS core region would permit critical immunochemical analysis of this portion of the LPS macromolecule as well as functional evaluation of the antibodies themselves. We have recently reported the preparation of such mAbs, of both murine (14) and human origin (15), and confirmatory data have come from several other laboratories (16) (17) (18) (19) (20) . We describe here the preparation of stable hybrid cell lines that secrete human mAbs that recognize conserved epitopes in the core-lipid A region of LPS. Characterization ofthese antibodies confirms the presence ofhighly conserved antigenic structures in the core-lipid A complex and proves the existence of human B cell clones capable ofsecreting high avidity antibodies that react with these widely shared determinants. These mAbs with core-lipid A specificity may be assayed directly for their protective effect and as prophylactic and/or therapeutic agents for diseases caused by gram-negative bacteria. minnesota wild-type strains were obtained from L. Shoer (List Biological Laboratories, Inc., Campbell, CA). Clinical isolates were obtained from the clinical microbiology laboratory, Naval Hospital, Bethesda, MD.
Lipopolysaccharides (LPS), lipid A, and part structures. Rough and smooth LPS, purified by Galanos (21) and modified Westphal procedures (22), respectively, and further purified chromatographically, were obtained from List Biological Laboratories. Quantitative analyses of 19 LPS preparations used were provided by the manufacturer. 14 (74%) contained < 1%, and all 19 contained < 1.5% nucleic acid by weight. 11 (58%) contained < 1%, and all 19 contained < 2% protein by weight. Lipid As, prepared by acetic acid hydrolysis ofRe mutant LPS (23), were obtained from List or from Ribi Immunochem Research, Inc., Hamilton, MT. Monophosphoryl lipid A (24), derived from Re mutant S. minnesota LPS, was obtained from Ribi. The lipid A precursor molecule designated lipid X (25), was purchased from Lipidex, Middleton, WI.
Enzyme-linked immunosorbent assays (ELISA). Antibody reactivity with rough and smooth LPS, and lipid A, was measured by ELISA, as previously described (8) . Briefly, LPS (or lipid A) dissolved in carbonate coating buffer (15 mM Na2CO3, 30 mM NaHCO3, 3 mM NaN3, pH 9.55), at a concentration of 10-25 Ag/ml, was incubated at 40C overnight in polystyrene microtiter plates (Dynatech Laboratories, Inc., Alexandria, VA). The wells were washed with phosphate-buffered saline (PBS, pH 7.4) containing 0.5 ml/liter of Tween-20 (PBS-Tween). Then, 50 1AI antibody-containing test samples (suspended in PBS-Tween) were incubated in the wells at 4VC for 30 min. The final three steps, separated by PBSTween washes, were as follows: addition of 50 Ml of rabbit anti-human Ig (Zymed, South San Francisco, CA) diluted 1:500, followed by incubation at 40C for 30 min; addition of 50 MAl of goat anti-rabbit IgGalkaline phosphatase conjugate (Sigma Chemical Co., St. Louis, MO); addition of 50 Ml ofp-nitrophenylphosphate substrate (Sigma 104), 1 1% 2-mercaptoethanol, and 0.001% bromophenol blue. The samples were run in a Laemmli SDS-polyacrylamide gel electrophoresis system (PAGE) (43), using the slab apparatus described by Maizel (44) , in which was employed a 4% stacking gel and a 14% separating gel incorporating 4 M urea. The sample mixtures were heated in a 1000C water bath for 5 min, applied in 10-20-Ml aliquots to a 140 X 120 X 1.2 mm slab gel, and electrophoresed at 20 mA/gel until the bromophenol blue had migrated 10 cm. The gel was then fixed by overnight incubation in a solution containing 40% ethanol and 5% acetic acid, and silver-stained according to the method of Tsai and Frasch (45) .
LPS was transferred from identical, unstained companion gels according to the procedure ofTowbin (46) , as modified by Hitchcock (47) , onto nitrocellulose membranes (Bio-Rad Laboratories, Richmond, CA) employing a transphor electrophoresis cell (TE42, Hoefer Scientific Instruments, San Francisco, CA). Transfers were performed in the cold employing a current of 125 mA for 20 h. Immunoblots were developed in the following manner. Nitrocellulose membranes containing transferred LPS were immersed for 10 min in Tris buffer with saline (TBS) containing 20 mM Tris-HCl and 150 mM NaCl, pH 7.5. Membranes were then immersed, with gentle agitation for 30 min, in blocking solution consisting of TBS plus 2% bovine serum albumin (BSA) and 0.25% gelatin. Membranes were then immersed in a solution containing the primary antibody, appropriately diluted in TBS plus 2% BSA, 0.25% gelatin, and 0.05% Tween-20 (TBS-AGT), and gently agitated for 2 h. Membranes were washed with distilled water in TBS-AGT and incubated for 2 h with a second antibody (e.g., rabbit anti-human IgM) at an appropriate dilution. Membranes were then washed as before and incubated with a third antibody (e.g., goat anti-rabbit IgG) conjugated with peroxidase and diluted appropriately in TBS-AGT. Color was developed by the addition of chloronaphthol substrate (60 mg in 20 ml of cold methanol mixed at room temperature with 100 mg of TBS to which 60 41 of cold 30% H202 had just been added), and color development stopped by immersing nitrocellulose membranes in several changes ofdistilled water.
Estimation ofantibody avidity. The solid-phase radioimmunoassay system employed was adapted from that previously described by Frankel and Gerhard (48) and later modified by Mandrell and Zollinger (49), except that LPS (or lipid A) was the solid-phase antigen used to coat the wells of flexible polyvinyl microtiter plates (overnight incubation at 4VC at an appropriate LPS concentration, as indicated below). Serial dilutions of mAb, prepared by ammonium sulfate precipitation of hybridoma tissue culture supernatant obtained under serum-free conditions, were incubated overnight at room temperature in LPS-coated microtiter plates. The amount ofspecific antibody bound at each dilution was determined by subsequent incubation with '251I-labeled goat anti-human immunoglobulin. The resulting counts per minute were related to a standard curve generated by means of a capture assay in which known amounts of human immunoglobulin of the appropriate class were added to microtiter wells previously treated with a class-specific rabbit anti-human immunoglobulin and detected with class-specific 1251I-labeled goat antihuman Ig. Antibody concentration at each dilution was determined by assaying a single antibody dilution in microtiter wells coated with increasing concentrations of LPS (lipid A) and establishing the peak antibody concentration above which no additional binding occurred with increasing amounts of antigen; the antibody concentration determined at this single dilution was then used to calculate the antibody concentration ofother dilutions by multiplying by the appropriate dilution factor. After quantitation oftotal LPS-specific antibody and antibody bound at each dilution, a Scatchard plot was constructed of antibody bound/free antibody vs. antibody bound, and Kq determined by the following formula: -nKY, = antibody bound/total antibody -antibody bound, where n = antibody valence (assumed to be 10 in the case of IgM).
LPS hydrolysis (23). 1 mg of purified smooth LPS was mixed with 3 ml of 1% acetic acid in a I0-ml capacity round-bottom flask. The mixture was refluxed for 2 h at 100°C, allowed to cool, and adjusted to pH 7.5 with 2 N NaOH. The hydrolyzed LPS was then diluted 1:10 in coating buffer and used to coat the wells of microtiter plates for determination of antibody binding in the ELISA (see above).
Results
Hybridomas (Fig. 3) . The greater inhibitory capacity of lipid As compared with core glycolipids, and of glycolipids compared with smooth parent LPS (Fig. 3) This was examined in a whole cell ELISA employing, as solidphase antigens, the E. coli J5 and S. minnesota R595 rough mutant strains and various wild type clinical isolates. As indicated by the representative binding data shown in Fig. 4 , the D-234, D-244, and D-267 mAbs reacted strongly with both E. coli J5 and S. minnesota R595 whole bacteria, corresponding to the isolated core glycolipids that these antibodies were previously shown to bind. D-250, on the other hand, demonstrated greater selectivity for E. coli J5 whole cells, which was similar to its specificity for isolated E. coli J5 LPS. While binding to whole, rough bacteria and corresponding isolated core glycolipids closely paralleled one another in the case ofall four mAbs, an interesting divergence was noted in the case of smooth bacteria. In contrast to the other lipid A-reactive mAbs, D-244 and D-267, and the core oligosaccharide-reactive mAb, D-250, none ofwhich reacted well with whole, smooth bacteria, D-234 demonstrated strong reactivity with a variety of clinical isolates (Fig. 4) despite its limited ability to bind isolated smooth LPS. In subsequent experiments (data not shown), maximal binding by D-234 to whole, smooth bacteria, obtained from carefully synchronized cultures, appeared to coincide with early log phase growth and to diminish markedly in late log and stationary phases.
Immunoblotting analysis. LPS consist of molecular species of varying molecular weight, reflecting variations in O-side chain length and core oligosaccharide integrity (50). Fast-migrating species can be resolved by SDS-PAGE carried out under reducing conditions and represent variants of the lipid A-core oligosaccharide complex. The exact mobility ofsuch a complex depends upon lipid A substitution patterns and fatty acid composition, as well as the integrity ofthe core oligosaccharide. LPS molecules that contain a complete core structure and covalently attached O-side chains appear on such gels as regularly spaced, slower migrating bands, with adjacent bands representing LPS molecules that differ from one another by a single oligosaccharide subunit in the 0-side chain (Fig. 5) (45) .
Immunoblots were developed with mAbs after separation of LPS subcomponents on SDS-PAGE gels and electrophoretic transfer onto nitrocellulose membranes. In this type of immunoblotting analysis, the lipid A-reactive mAb, D-234, recognized its epitope only on fast-migrating species. Optimal reactivity was demonstrated by this antibody against Re chemotype LPS derived from S. minnesota (Fig. 5, lane 12 ) and E. coli K12 (strain D31m4, lane 5), and against free lipid As obtained from S. minnesota, S. typhimurium, and E. coli K12 (lanes 13, 15, and 6). D-234 also recognized its antigenic determinant on the larger core structure of the E. coli J5 Rc chemotype mutant (Fig. 5,  lane 2) , and showed minor reactivity with LPS obtained from S. minnesota rough mutants representing the Ra, Rb, Rc, and Rd chemotypes (lanes 8-11) . In the latter instances, however, the equivalent, fast migration pattern of the blots suggested that D-234 was actually reacting with small amounts of free lipid A released from these core glycolipids rather than with the intact as well as at least one member of the Pseudomonadaceae. The mAb D-250 reacted selectively with LPS from the Rc chemotype of S. Minnesota, the analogous J5 mutant of E. coli 011 1:B4, and the E. coli K12 BB26:36 strain which on silverstained SDS-PAGE gels also appeared to lack O-side chains ( Fig.  5; lanes 10, 2, and 4, respectively) . The recognition by D-250 of its epitope in the Rc form of S. Minnesota LPS, alone among the various rough chemotypes tested, confirmed the specificity of this mAb for a determinant in the core oligosaccharide and underscored the importance of adequate epitope exposure. The apparent reactivity of D-250 with E. coli J5 lipid A (lane 3) reflects probable contamination of the lipid A preparation with unhydrolyzed J5 LPS, as described above. Supporting this interpretation were the intense staining ofthis lipid A preparation on silver-stained SDS-PAGE gels (weak or absent in the case of other lipid As-see lanes 6, 13, 15, and 16); the presence of KDO, as revealed by thiobarbituric acid assay; and the absence of reactivity of D-250 with other lipid As (lanes 6, 13, and 15) . The observation that binding patterns developed with mAb D-250 appeared to be broader and to embrace somewhat slower migrating molecular species than those produced in immunoblots with D-234 also indicated that D-250 recognized a more distal determinant in the incomplete core oligosaccharide. Conversely, D-234, but not D-250, reacted strongly with a monophosphoryl derivative of S. typhimurium lipid A (Fig. 5, (Table II) . The binding constants were somewhat higher for free lipid As compared with the corresponding core glycolipids. It was thus documented that a broadly cross-reactive lipid A-specific mAb may display high avidity for an epitope shared by phylogenetically distinct gram-negative bacteria.
Inhibition of mAbs by polymyxin B. It is well known that the cell wall-active cationic antibiotic, polymyxin B, inhibits many of the biologic activities of LPS on the basis of its specific interaction with the lipid A moiety (51) . It was therefore of interest to examine the possible inhibitory effect of polymyxin B on the reactivity of core-specific mAbs with their respective epitopes. Using the competitive inhibition ELISA format described above and graded concentrations of polymyxin B inhibitor, we demonstrated dose-dependent inhibition ofbinding by the lipid A-specific mAbs D-234 and D-267 (Fig. 6, left panel) among bacterial species in respect to lipid A structure and/or variable susceptibility ofparticular epitopes to structural or conformational alteration resulting from acid hydrolysis as carried out in this study. Interestingly, antisera included as "positive controls," which recognized determinants in the exposed O-side chain ofsmooth LPS, produced almost equivalent high reactivity against hydrolyzed and unhydrolyzed homologous LPS (Table  I ). In contrast, these antisera demonstrated low reactivity against heterologous smooth LPS, but marked enhancement in epitope recognition following release of free lipid A by acid hydrolysis comparable to that observed in the case oflipid A-reactive mAbs. Thus, shared antigenic determinants in the core-lipid A region of LPS must be exposed in order to be recognized by core-specific antibodies, whether ofmonoclonal or polyclonal origin. A previous study (18) reported the identification of a hybridoma, resulting from the fusion of B lymphocytes from a "sensitized" human spleen with heteromyeloma cells, that produced a human IgM antibody that purportedly reacted with all rough and smooth LPS and all gram-negative bacterial isolates examined. It was further asserted that this antibody neutralized each oftwo LPS employed in the induction oflocal Shwartzman reactions and protected, without exception, against each of five phenotypically smooth heterologous gram-negative bacteria in live challenge experiments. Although the lipid A specificity and cross-reactivity of the human mAb described in this previous study suggested similarities to the human mAbs reported here, the uniformly positive binding and functional activities of this mAb vis-a-vis all rough and smooth LPS (and bacteria) tested were not fully consistent with our results, or with those reported by others in respect to murine mAbs with similar specificities (17, 19, 20 
